Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 2/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30157756 | 1.00 | MEN1 (0.63) | MEN1KMT2AALOX5APFEN1PARP1 | |
| SCHEMBL15108903 | 0.95 | MEN1 (0.61) | MEN1KMT2AALOX5APFEN1PARP1 | |
| SCHEMBL12478981 | 0.81 | GFER (0.45) | MEN1KMT2AALOX5APFEN1MGLL | |
| SCHEMBL7787664 | 0.79 | HSD17B10 (0.53) | MEN1KMT2AALOX5APFEN1MGLL | |
| SCHEMBL9360420 | 0.79 | ADRA1B (0.51) | PARP1HSD17B10TP53ALDH1A1 | |
| SCHEMBL22997585 | 0.78 | HSD17B10 (0.44) | MEN1KMT2AALOX5APFEN1MGLL | |
| SCHEMBL5436101 | 0.78 | ALOX5 (0.54) | MGLLHSD17B10TP53ALDH1A1 | |
| SCHEMBL1901693 | 0.78 | DDB1 (0.56) | MEN1KMT2AHSD17B10 | |
| SCHEMBL3842955 | 0.78 | HSD17B10 (0.44) | MEN1KMT2AALOX5APFEN1MGLL | |
| SCHEMBL8902463 | 0.78 | NPC1 (0.49) | MEN1KMT2AALOX5APFEN1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112262140-B | Pesticidally active heterocyclic derivatives with sulfoximine containing substituents | 先正达农作物保护股份公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-109843886-A | Two ring pyridone lactams and its application method | 豪夫迈·罗氏有限公司 | 2019-06-04 | — | — | CN | disclosed |
| CN-103877080-B | 4,5-bis-replaces-medicinal usage of 2-Pyrrolidone compound | Key Laboratory of natural product chemistry, Chinese Academy of Sciences, Guizhou Province (CN) | 2016-01-27 | — | — | CN | disclosed |
| CN-103877080-A | New use of 4, 5-disubstituted-2-pyrrolidone compound | KEY LAB OF CHEMISTRY NATURAL PRODUCTS OF GUIZHOU PROVINCE AND CHINESE ACADEMY | 2014-06-25 | — | — | CN | disclosed |
| CN-101979378-B | Method for synthesizing chiral gamma-lactam compounds | SHANGHAI INST ORGANIC CHEM | 2012-06-27 | — | — | CN | disclosed |
| CN-101979378-A | Method for synthesizing chiral gamma-lactam compounds | SHANGHAI INST ORGANIC CHEM | 2011-02-23 | — | — | CN | disclosed |
| US-7846933-B2 | such as 1-(4-Fluorophenyl)-5-(pyridin-4-yl)-4-imidazolin-2-one, having excellent p38 MAP kinase inhibitory action, useful for the treatment of osteoarthritis, arthritis, ulcerative colitis, Crohn's disease, psoriasis, dermatitis, asthma, bronchitis, pneumonia, rhinitis, conjunctivitis or keratitis | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-12-07 | — | — | US | disclosed |
| US-20090088422-A1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | KUBO AKIRA | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088422-A1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | OR10J3, NR4A3, NR3C2 | MEN1 1829/4885KMT2A 1710/4885ALOX5AP 3790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.